{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T14:55:58Z","timestamp":1724856958124},"reference-count":0,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>Withdrawal: McGirr, K., Sarkar, S., Subramanian, K. (2023) \u201cQuantitative modeling of approved and emerging therapeutics for modifying TTR levels in patients with Transthyretin Amyloid Cardiomyopathy\u201d <jats:italic>CPT: Pharmacometrics &amp; Systems Pharmacology<\/jats:italic>. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/doi.org\/10.1002\/psp4.13078\">https:\/\/doi.org\/10.1002\/psp4.13078<\/jats:ext-link>.<\/jats:p><jats:p>The above article, published online on November 6, 2023, in Wiley Online Library (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/wileyonlinelibrary.com\">http:\/\/wileyonlinelibrary.com<\/jats:ext-link>), has been withdrawn by agreement between the authors, journal Editor\u2010in\u2010Chief, France Mentr\u00e9, the American Society for Clinical Pharmacology and Therapeutics (ASCPT), and Wiley Periodicals LLC. The withdrawal has been agreed to at the authors' request due to a disagreement over the ownership of some data contained therein.<\/jats:p>","DOI":"10.1002\/psp4.13078","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T05:21:41Z","timestamp":1699334501000},"page":"1278-1278","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["WITHDRAWAL: Quantitative modeling of approved and emerging therapeutics for modifying TTR levels in patients with Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1002","volume":"13","member":"311","published-online":{"date-parts":[[2024,6,19]]},"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.13078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T09:00:58Z","timestamp":1724144458000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.13078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":0,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1002\/psp4.13078"],"URL":"https:\/\/doi.org\/10.1002\/psp4.13078","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"type":"print","value":"2163-8306"},{"type":"electronic","value":"2163-8306"}],"subject":[],"published":{"date-parts":[[2024,6,19]]},"assertion":[{"value":"2024-06-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}